SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing
Based on Highly-Purified Isomers of Tannic Acid and Acting as a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir Has Shown Significant Anti-Viral Properties with Minimal Observed Side Effects NEW TAIPEI CITY, Taiwan and TORRANCE, Calif., Nov. 20, 2021 /PRNewswire/ -- SyneuRx™ International, (Taipei Exchange, ticker ID TT6575, www.syneurx.com), a pioneering developer of novel CNS (Central Nervous System) and anti-viral pharmaceuticals, today...
UAE to receive award from Parliamentary Assembly of the Mediterranean for Waterfalls Initiative
ROME, Nov. 19, 2021 /PRNewswire/ -- On Thursday November 18, in the Sala Protomoteca of the Campidoglio in Rome, the United Arab Emirates, represented by Saif bin Zayed, Deputy Prime Minister and Minister of the Interior received an award from the Parliamentary Assembly of the Mediterranean (PAM) for Waterfalls, a global initiative launched by the UAE Ministry of Possibilities,...
Brii Biosciences Joins Hang Seng Composite Index
DURHAM, N.C. and BEIJING, Nov. 19, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), today announced that Brii Biosciences has been included as a constituent stock of the Hang Seng Composite Index. Dr. Ankang Li, Chief Financial Officer and Joint Company Secretary of Brii Biosciences, commented, "The inclusion...
Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma
SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Nov. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...
Kangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported for the First Time
SHENZHEN, China, Nov. 19, 2021 /PRNewswire/ -- At 3 a.m. on November 19, the first batch of more than 4 million doses of adenovirus vector COVID-19 vaccines produced by Shenzhen Kangtai Biological Products Co., Ltd. will depart from Shenzhen Bao'an International Airport and will arrive in Jakarta, capital of Indonesia, at 9 a.m. on November 19, local time....
Vazyme Attends Medica 2021 in Germany to Accelerate Its Global Market Expansion
DUSSELDORF, Germany, Nov. 19, 2021 /PRNewswire/ -- Chinese biotechnology company Vazyme (688105.SH) recently attended Medica 2021 in Germany—one of the world's largest events for the medical sector—to accelerate the expansion of its international business. At the event, Vazyme introduced its newest 3-in-1 virus testing solutions, SARS-CoV-2 Ag & FLU A/B Rapid Test and SARS-CoV-2, Influenza A/B RT-QPCR Detection Kit...
Experts warn that post-COVID hygiene lethargy could put millions at risk of fatal infections due to antimicrobial resistance
LONDON, Nov. 19, 2021 /PRNewswire/ -- With over 5 million deaths worldwide, COVID-19 has imposed a significant burden on societies and healthcare systems around the world. As we continue to address the impact of COVID-19, there is an even greater public health threat which must be tackled, AMR. The importance of hygiene's role in breaking the chain of infection...
111, Inc. Announces Third Quarter 2021 Unaudited Financial Results
SHANGHAI, Nov. 19, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the third quarter ended September 30, 2021. Third Quarter 2021 Highlights Net revenues were RMB3.35 billion (US$519.3 million), representing an increase of...
ASRA 2021 | Cali Biosciences Presents Phase IIa Clinical Data on CPL-01, a Long-Acting Ropivacaine
SAN DIEGO, Nov. 19, 2021 /PRNewswire/ -- Cali Biosciences, a global biopharmaceutical company focused on the research and development of innovative drugs, presented Phase IIa clinical data today on its perioperative long-acting ropivacaine, CPL- 01, at the 20th Annual American Society of Regional Anesthesia and Pain Medicine (ASRA) Meeting. CPL-01 is an extended-release injectable version of ropivacaine hydrochloride developed...
Treating Patients Beyond Borders – Antengene Successfully Hosted Its First R&D Day
- Highlighted R&D Strategy and Broad Pipeline of 15 Programs including 10 with Worldwide Rights - ATG-010's First Approval in Asia transforms Antengene into a Commercial Entity, 10 Studies in ATG-010 being Conducted in Mainland China - Exciting ATG-008 (mTORC1/2 inhibitor) Signal, ATG-017 (ERK1/2 inhibitor) Progress, and ATG-101 (PD-L1/4-1BB bispecific antibody)...
